Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors
“Therapy resistance and metastatic dissemination are the main challenges in developing effective cancer treatments. Cancer stem cells and tumor-initiating cells play a significant role in this, and until now, have only been poorly characterized. We have completed extensive preclinical studies to support the clinical advancement of TACH101, and we have shown its ability to reduce the population of tumorigenic cells and potently shrink tumors in cancer models,” said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapeutics. “We are pleased to receive the support of CIRM to advance the first KDM4 inhibitor to enter clinical development.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.